Vir Biotechnology, Inc.

VIR Healthcare Biotechnology

Revenue
−178.3%
EPS
+51.4%
Free cash flow
+200.5%

Quarter to September 2026, against a year earlier

12.19 1.17 +10.62%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
−6.5×
Dividend yield
—
F-score
4/9
Altman Z
−0.57
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 10.42 6.37 0.00 0.00 0.00
Piotroski F-Score
— — — 5 4 5 3 4 4
P/S ratio
0.00 14.73 47.19 41.79 4.96 2.05 16.36 13.48 12.18
Altman Z-Score
— — 1.27 8.36 8.17 5.39 2.04 1.11 (0.57)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 2.07 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
— (5.30) 4.77 4.00 8.19 10.15 7.11 4.60 (0.97)
P/Operating CF
0.00 (3.98) (9.82) (38.89) 706.73 94.08 (13.06) (11.41) (32.28)
P/B ratio
0.00 0.00 0.90 4.45 3.80 1.59 0.89 0.87 1.09
EV/Sales
0.00 (18.19) (0.97) 32.03 4.31 0.55 (1.46) 0.07 5.34
EV/EBITDA
0.00 1.25 0.05 0.00 11.08 1.07 0.19 0.00 0.00
EV/FCF
0.00 1.39 0.06 (12.40) (68.03) 0.56 0.16 (0.01) (0.92)
Current Ratio
16.00 2.95 6.81 7.80 4.58 4.93 9.05 8.71 5.54
Net Debt/EBITDA
2.32 0.94 2.24 2.58 (1.68) (2.91) 2.28 1.75 1.02
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
56.33% 93.39% (142.74%) (52.36%) 49.20% 29.39% (33.53%) (38.09%) (45.73%)
ROA
(31.46%) (120.97%) (49.65%) (41.75%) 36.80% 21.69% (26.06%) (31.46%) (36.47%)
ROIC
0.00% 0.00% (324.07%) 0.00% 36.77% 0.00% (783.90%) (235.77%) (101.09%)
Return on Tangible Assets
(37.76%) (128.52%) (48.51%) (43.21%) 41.80% 24.40% (40.76%) (52.94%) (91.84%)
Average Days of Receivables
0.00 0.00 0.00 0.00 257.60 0.00 0.00 0.00 0.00
Earnings Yield
(51.20%) (111.14%) (96.28%) (9.26%) 9.60% 15.69% (43.67%) (52.04%) (52.40%)
Free Cash Flow Yield
0.00% (88.60%) (36.29%) (6.18%) (1.28%) 48.27% (56.77%) (45.03%) (47.45%)
Free Cash Flow per Share
(32.12) (13.34) (4.57) (1.66) (0.53) 12.03 (5.97) (3.30) (2.86)
Book value per Share
0.00 (23.37) 13.97 6.02 11.02 15.67 11.86 8.44 5.52
Free Cash Flow
(69.12) (102.26) (138.57) (197.31) (69.41) 1,595.25 (800.36) (450.28) (396.36)
EV/EBIT
0.00 1.22 0.04 0.00 11.22 1.07 0.18 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026